Cobalamin deficiency, hyperhomocysteinemia, and dementia

被引:0
作者
Werder, Steven F. [1 ,2 ]
机构
[1] Community Hlth Ctr SE Kansas, Pittsburg, KS 66762 USA
[2] Univ Kansas, Sch Med Wichita, Wichita, KS USA
关键词
Alzheimer; dementia; cognitive impairment; cognitive dysfunction; cobalamin; cyanocobalamin; B12; homocysteine; hyperhomocysteinemia; homocystinuria; MILD COGNITIVE IMPAIRMENT; PLASMA HOMOCYSTEINE LEVELS; FOLIC-ACID SUPPLEMENTATION; MEDIAL TEMPORAL-LOBE; METHYLENETETRAHYDROFOLATE REDUCTASE GENE; CONFIRMED ALZHEIMERS-DISEASE; SERUM METHYLMALONIC ACID; S-ADENOSYL-METHIONINE; WHITE-MATTER CHANGES; FUNCTIONAL VITAMIN-B-12 DEFICIENCY;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: Although consensus guidelines recommend checking serum B12 in patients with dementia, clinicians are often faced with various questions: (1) Which patients should be tested? (2) What test should be ordered? (3) How are inferences made from such testing? (4) In addition to serum B12, should other tests be ordered? (5) Is B12 deficiency compatible with dementia of the Alzheimer's type? (6) What is to be expected from treatment? (7) How is B12 deficiency treated? Methods: On January 31st, 2009, a Medline search was performed revealing 1,627 citations related to cobalamin deficiency, hyperhomocysteinemia, and dementia. After limiting the search terms, all abstracts and/or articles and other references were categorized into six major groups (general, biochemistry, manifestations, associations and risks, evaluation, and treatment) and then reviewed in answering the above questions. Results: The six major groups above are described in detail. Seventy-five key studies, series, and clinical trials were identified. Evidence-based suggestions for patient management were developed. Discussion: Evidence is convincing that hyperhomocysteinemia, with or without hypovitaminosis B12, is a risk factor for dementia. In the absence of hyperhomocysteinemia, evidence is less convincing that hypovitaminosis B12 is a risk factor for dementia. B12 deficiency manifestations are variable and include abnormal psychiatric, neurological, gastrointestinal, and hematological findings. Radiological images of individuals with hyperhomocysteinemia frequently demonstrate leukoaraiosis. Assessing serum B12 and treatment of B12 deficiency is crucial for those cases in which pernicious anemia is suspected and may be useful for mild cognitive impairment and mild to moderate dementia. The serum B12 level is the standard initial test: 200 picograms per milliliter or less is low, and 201 to 350 picograms per milliliter is borderline low. Other tests may be indicated, including plasma homocysteine, serum methylmalonic acid, antiparietal cell and anti-intrinsic factor antibodies, and serum gastrin level. In B12 deficiency dementia with versus without pernicious anemia, there appear to be different manifestations, need for further workup, and responses to treatment. Dementia of the Alzheimer's type is a compatible diagnosis when B12 deficiency is found, unless it is caused by pernicious anemia. Patients with pernicious anemia generally respond favorably to supplemental B12 treatment, especially if pernicious anemia is diagnosed early in the course of the disease. Some patients without pernicious anemia, but with B12 deficiency and either mild cognitive impairment or mild to moderate dementia, might show some degree of cognitive improvement with supplemental B12 treatment. Evidence that supplemental B12 treatment is beneficial for patients without pernicious anemia, but with B12 deficiency and moderately-severe to severe dementia is scarce. Oral cyanocobalamin is generally favored over intramuscular cyanocobalamin.
引用
收藏
页码:159 / 195
页数:37
相关论文
共 50 条
  • [21] Treatment of cobalamin deficiency in dementia, evaluated clinically and with cerebral blood flow measurements
    Nilsson, K
    Warkentin, S
    Hultberg, B
    Fäldt, R
    Gustafson, L
    AGING-CLINICAL AND EXPERIMENTAL RESEARCH, 2000, 12 (03) : 199 - 207
  • [22] Emodin Rescued Hyperhomocysteinemia-Induced Dementia and Alzheimer's Disease-Like Features in Rats
    Zeng, Peng
    Shi, Yan
    Wang, Xiao-Ming
    Lin, Li
    Du, Yan-Jun
    Tang, Na
    Wang, Qun
    Fang, Ying-Yan
    Wang, Jian-Zhi
    Zhou, Xin-Wen
    Lu, Youming
    Tian, Qing
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2019, 22 (01) : 57 - 70
  • [23] Diagnosis of cobalamin deficiency: The old and the new
    Chanarin, I
    Metz, J
    BRITISH JOURNAL OF HAEMATOLOGY, 1997, 97 (04) : 695 - 700
  • [24] SERUM COBALAMIN AND METHYLMALONIC ACID IN ALZHEIMER DEMENTIA
    KRISTENSEN, MO
    GULMANN, NC
    CHRISTENSEN, JEJ
    OSTERGAARD, K
    RASMUSSEN, K
    ACTA NEUROLOGICA SCANDINAVICA, 1993, 87 (06): : 475 - 481
  • [25] Screening for cobalamin deficiency in geriatric outpatients: Prevalence and influence of synthetic cobalamin intake
    Rajan, S
    Wallace, JI
    Beresford, SAA
    Brodkin, KI
    Allen, RA
    Stabler, SP
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2002, 50 (04) : 624 - 630
  • [26] Cobalamin deficiency in adults
    Loukili, NH
    Andrès, E
    ANNALES D ENDOCRINOLOGIE, 2003, 64 (05) : 376 - 382
  • [27] Management of cobalamin deficiency
    Le Guenno, Guillaume
    Quilliot, Didier
    NUTRITION CLINIQUE ET METABOLISME, 2014, 28 (02): : 130 - 134
  • [28] Homocysteine in the context of cobalamin metabolism and deficiency states
    Briddon, A
    AMINO ACIDS, 2003, 24 (1-2) : 1 - 12
  • [29] Communication: Melatonin, Hyperhomocysteinemia, Thioretinaco Ozonide, Adenosylmethionine and Mitochondrial Dysfunction in Aging and Dementia
    McCully, Kilmer S.
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2018, 48 (01) : 126 - 131
  • [30] Homocysteine in the context of cobalamin metabolism and deficiency states
    A. Briddon
    Amino Acids, 2003, 24 : 1 - 12